CTA, MRA Aneurysm Screening Technologies Appraised By Neuroradiologists
This article was originally published in The Gray Sheet
Executive Summary
Computed tomography angiography (CTA) will likely supplant traditional x-ray angiography as the basis for decisions on treating sub-arachnoid aneurysms, according to Joseph Heiserman, MD, Barrow Neurological Institute, Phoenix
You may also be interested in...
FDA In Brief
Clinical literature guidance: FDA is considering a collaboration with the National Institutes of Health and the Centers for Medicare & Medicaid Services on a guidance aimed at the use of literature to support claims. The device center and industry had been working on a genetic testing guidance addressing the use of literature in lieu of prospective trials (1"The Gray Sheet" Sept. 3, 2001, p. 8). That effort is currently "stalled," according to CDRH Division of Clinical Laboratory Devices Director Steven Gutman, who notes, however, that it could be revived via HHS intra-departmental collaboration. "NIH is interested in looking at use of clinical literature, and CMS is interested in looking at clinical literature. We are being instructed by [HHS Secretary] Tommy Thompson to behave as one department and try and actually be consistent across agencies," the DCLD director reports at the Association of Medical Diagnostics Manufacturers annual meeting...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.